Patents by Inventor Tobias LITZENBURGER

Tobias LITZENBURGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD40 ANTIBODIES
    Publication number: 20170058039
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 2, 2017
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • ANTI-CD40 ANTIBODIES
    Publication number: 20160222124
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • ANTIBODIES FOR GUANYLYL CYCLASE RECEPTORS
    Publication number: 20160168251
    Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.
    Type: Application
    Filed: June 19, 2015
    Publication date: June 16, 2016
    Inventors: Alisa WATERMAN, Daniel RAJOTTE, Tobias LITZENBURGER, Alexandra KRAUS
  • ANTI-CD40 ANTIBODIES
    Publication number: 20150315282
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 18, 2015
    Publication date: November 5, 2015
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20150210778
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: April 13, 2015
    Publication date: July 30, 2015
    Inventors: Joanne VAN RYN, John Edward PARK, Norbert HAUEL, Ulrich KUNZ, Tobias LITZENBURGER, Keith CANADA, Sanjaya SINGH, Alisa K. WATERMAN
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20150118225
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: October 23, 2014
    Publication date: April 30, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Herbert NAR, Felix SCHIELE, Daniel SEELIGER, Joanne VAN RYN
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20140377265
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: July 22, 2014
    Publication date: December 25, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
  • ANTI-CD40 ANTIBODIES
    Publication number: 20140179907
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: October 4, 2013
    Publication date: June 26, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20130289248
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 31, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, John Edward PARK, Norbert HAUEL, Ulrich KUNZ, Tobias LITZENBURGER, Keith CANADA, Sanjaya SINGH, Alisa WATERMAN
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20120276123
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: March 28, 2012
    Publication date: November 1, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
  • Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
    Publication number: 20110311553
    Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 22, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Sandra MILLER, Catrin PRACHT, Rainer BOXHAMMER, Jeanne MAGRAM, Patricia GIBLIN, Daniel RAJOTTE
  • ANTI-CD40 ANTIBODIES
    Publication number: 20110243932
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: March 30, 2011
    Publication date: October 6, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
    Publication number: 20100119506
    Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
    Type: Application
    Filed: July 30, 2009
    Publication date: May 13, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Sandra MILLER, Catrin PRACHT, Rainer BOXHAMMER, Jeanne MAGRAM, Patricia GIBLIN, Daniel RAJOTTE